Swedish Orphan Biovitrum Shares Fall After Forecast Cut on European Sales

Swedish Orphan Biovitrum AB fell the most in more than a year in Stockholm trading after cutting its full-year forecast.

Swedish Orphan said sales will increase by 1 percent to 4 percent compared with its earlier forecast of 8 to 10 percent, because of weaker sales than expected in Europe. Shares in the Stockholm-based drugmaker fell as much as 8.2 percent, the steepest decline since July 2009, and were down 1.90 kronor, or 4.6 percent, to 39.50 kronor at 9:14 a.m. local time.

To contact the editor responsible for this story: Frances Schwartzkopff at fschwartzko1@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.